

3 F
3NF
17F
17NF
21F
21NF
30F
30NF
34F
34NF
43F
43NF
IL-2 (p g.ml)
5000
4000
3000
2000
1000
0
36-50
37-51
38-52
39-53
40-54
41-55
42-56
43-57
44-58
45-59
46-60
PBS

FIG. 1



MOG14 ROK5 in vitro tolerisation run#2
P<0.05
P<0.05
P<0.05
P<0.05
IS
15
10
05
0
PBS/100
PBS/10
PBS/1
PBS/0.1
PBS/0.01
ROK5/100
ROK5/10
ROK5/1
ROK5/0.1
ROK5/0.01
MOG35/100
MOG35/10
MOG35/1
MOG35/0.1
MOG35/0.01

FIG. 2



IL-10
IL-6
IL-17
GM-CSF
IL-2
IF Ng
pg/ml
PBS/0
PBS/10
MOG/0
MOG/10
ROK5/0
ROK5/10

FIG. 3



A
100 µg hu or mROK5
or PBS s.c
200µg mMOG35_55/CFA
tail base
d-8
d-6
d-4
d0
d2
EAE monitoring over 30 days
PTx
B
100 µg hu or mROK5
or PBS s.c
200µg mMOG35_55/CFA
tail base
d-15
d-13
d-11
d-8
d-6
d-4
d0
d2
EAE monitoring
over 30 days
PTx

FIG. 4



A
2.5
2.0
1.5
1.0
0.5
0.0
EAE score (mean +/- SEM)
100ug mMOG35_55
200ug mMOG35_55
5
10
15
20
25
30
35
days post-immunisation
B
120
110
100
90
initial body weight % mean
200ug
100ug
0
10
20
30
days post-immunisation

FIG. 5



A
2.0
1.5
1.0
0.5
0.0
Clinical Score (mean + sem)
PBS (vehicle)
huROK5
mROK5
5
10
15
20
25
30
Days Post-Immunisation
B
20
15
10
5
0
Disease Burden
PBS
mROK5
huROK5
0
5
10
15
20
25
30
days post-immunisation

FIG. 6



PBS
huROK5
Disease Burden
8
6
4
2
0
0
5
10
15
20
25
30
days post-immunisation

FIG. 7